FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2226559711> ?p ?o ?g. }

• W2226559711 endingPage "7630" @default.
• W2226559711 startingPage "7630" @default.
• W2226559711 abstract "7630 Background: Prognostic models for SCLC are using performance score (PS), laboratory tests or disease stage assessed by imaging tests. Even the recently introduced TNM system show that increasing from stage 1A (T1N0M0, 5 year survival 38%) to stage IV (metastasized, 5 year survival 1%) still provides us with a poor prognostic assessment. In this study we evaluated the use of CTC as a prognostic marker for Overall Survival (OS) in SCLC. Methods: In an ongoing study, patients (pts) with pathological proven SCLC were treated with firstline cisplatin /etoposide for a maximum of 4 cycles. Prior to the start, prior to the second cycle and at the end of chemotherapy 20 mL of whole blood was drawn and within 72 hours analyzed for circulating cells using CellTracks technology at a central laboratory (Veridex, Enschede, the Netherlands). Pts were staged as limited or extensive disease (IASLC 2009). Clinical data and CTC characteristics were analyzed in a blinded fashion. Pts were stratified into unfavorable and favorable prognostic groups based on CTC levels ≥ 2 or < 2 CTCs/7.5 mL, respectively. OS was analyzed in a Cox regression analysis using as covariates disease stage, PS and CTC before therapy or CTC decrease of at least 50% after the first cycle of chemotherapy. Results: A total of 41 pts with pathologically proven SCLC were included. Median (range) age was 66 yrs (47-84), male/female 26/15, PS 0/1/2/3 is 14/22/2/3, stage LD/ED 17/24, median (range) number of CTC is 9.5 (0-9909), 30 pts had ≥ 2 CTC at baseline. 33 pts were evaluable for CTC after one cycle of chemotherapy and 26 showed a decrease in CTCs of 50% or more. Median (range) OS was 240 days (219- 377). The predefined favorable prognostic group (baseline < 2 CTC count) was the most important prognostic factor (HR 3.3) after correction for age, sex, PS and stage. A decrease of at least 50% in CTC after one cycle of chemotherapy was the strongest prognostic factor (HR 0.015, 95%CI, 0.02-0.125, p < 0.0001) after correcting for baseline CTC, age, sex, PS and stage. Conclusions: Baseline CTCs and early decrease in CTCs in firstline chemotherapy are an independent predictive factor for OS in SCLC. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Veridex/Immunicon Veridex LLC Veridex LLC" @default.
• W2226559711 created "2016-06-24" @default.
• W2226559711 creator A5014311522 @default.
• W2226559711 creator A5023771574 @default.
• W2226559711 creator A5031620636 @default.
• W2226559711 creator A5044485173 @default.
• W2226559711 creator A5069451097 @default.
• W2226559711 creator A5078862785 @default.
• W2226559711 creator A5082306474 @default.
• W2226559711 creator A5089293856 @default.
• W2226559711 creator A5090194060 @default.
• W2226559711 date "2010-05-20" @default.
• W2226559711 modified "2023-10-06" @default.
• W2226559711 title "Circulating tumor cells (CTC) in small cell lung cancer (SCLC), a promising prognostic factor." @default.
• W2226559711 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.7630" @default.
• W2226559711 hasPublicationYear "2010" @default.
• W2226559711 type Work @default.
• W2226559711 sameAs 2226559711 @default.
• W2226559711 citedByCount "1" @default.
• W2226559711 countsByYear W22265597112019 @default.
• W2226559711 crossrefType "journal-article" @default.
• W2226559711 hasAuthorship W2226559711A5014311522 @default.
• W2226559711 hasAuthorship W2226559711A5023771574 @default.
• W2226559711 hasAuthorship W2226559711A5031620636 @default.
• W2226559711 hasAuthorship W2226559711A5044485173 @default.
• W2226559711 hasAuthorship W2226559711A5069451097 @default.
• W2226559711 hasAuthorship W2226559711A5078862785 @default.
• W2226559711 hasAuthorship W2226559711A5082306474 @default.
• W2226559711 hasAuthorship W2226559711A5089293856 @default.
• W2226559711 hasAuthorship W2226559711A5090194060 @default.
• W2226559711 hasConcept C121608353 @default.
• W2226559711 hasConcept C126322002 @default.
• W2226559711 hasConcept C143998085 @default.
• W2226559711 hasConcept C146357865 @default.
• W2226559711 hasConcept C151730666 @default.
• W2226559711 hasConcept C2776256026 @default.
• W2226559711 hasConcept C2776694085 @default.
• W2226559711 hasConcept C2778119113 @default.
• W2226559711 hasConcept C2779013556 @default.
• W2226559711 hasConcept C50382708 @default.
• W2226559711 hasConcept C61238886 @default.
• W2226559711 hasConcept C71924100 @default.
• W2226559711 hasConcept C86803240 @default.
• W2226559711 hasConceptScore W2226559711C121608353 @default.
• W2226559711 hasConceptScore W2226559711C126322002 @default.
• W2226559711 hasConceptScore W2226559711C143998085 @default.
• W2226559711 hasConceptScore W2226559711C146357865 @default.
• W2226559711 hasConceptScore W2226559711C151730666 @default.
• W2226559711 hasConceptScore W2226559711C2776256026 @default.
• W2226559711 hasConceptScore W2226559711C2776694085 @default.
• W2226559711 hasConceptScore W2226559711C2778119113 @default.
• W2226559711 hasConceptScore W2226559711C2779013556 @default.
• W2226559711 hasConceptScore W2226559711C50382708 @default.
• W2226559711 hasConceptScore W2226559711C61238886 @default.
• W2226559711 hasConceptScore W2226559711C71924100 @default.
• W2226559711 hasConceptScore W2226559711C86803240 @default.
• W2226559711 hasIssue "15_suppl" @default.
• W2226559711 hasLocation W22265597111 @default.
• W2226559711 hasOpenAccess W2226559711 @default.
• W2226559711 hasPrimaryLocation W22265597111 @default.
• W2226559711 hasRelatedWork W167319750 @default.
• W2226559711 hasRelatedWork W2108334876 @default.
• W2226559711 hasRelatedWork W2277416945 @default.
• W2226559711 hasRelatedWork W2413020017 @default.
• W2226559711 hasRelatedWork W2419189404 @default.
• W2226559711 hasRelatedWork W2470989873 @default.
• W2226559711 hasRelatedWork W2480785262 @default.
• W2226559711 hasRelatedWork W2600735778 @default.
• W2226559711 hasRelatedWork W3031390371 @default.
• W2226559711 hasRelatedWork W4294941672 @default.
• W2226559711 hasVolume "28" @default.
• W2226559711 isParatext "false" @default.
• W2226559711 isRetracted "false" @default.
• W2226559711 magId "2226559711" @default.
• W2226559711 workType "article" @default.